You just read:

Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer

News provided by

Merck

Jul 01, 2016, 05:30 ET